
    
      A total of 300 eligible subjects will be randomized in a 1:1 ratio to receive either
      convalescent plasma (CP) from people who have recovered from COVID-19 containing antibodies
      to SARS-CoV-2 or a placebo control, Lactated Ringer's Solution (LR) or saline solution (SS).
      Hospitalized COVID-19 patients aged â‰¥18 years of age with respiratory symptoms within 3 to 7
      days from the onset of illness OR within 3 days of hospitalization will be eligible to
      participate.
    
  